Japan-based Astellas Pharma is setting up a new facility in Cambridge, Mass. which is in line with the company’s 2016 strategic focus on innovation and enhancing its capabilities in developing dynamic new treatments to address unmet medical needs.
More than 300 companies are marketing unapproved stem cell procedures at more than 500 clinics in the U.S.
The fast-growing cell therapy market is attracting government and private funds, positioning disruption throughout the pharmaceutical landscape.
Waltham, Mass.-based AMAG Pharmaceuticals, Inc. (AMAG) announced today that it will acquire Cord Blood Registry (CBR) for $700 million. Last year, in November, AMAG acquired Lumara Health Inc., a specialty pharmaceutical company focused on maternal health. That deal had an upfront consideration of $600 million in cash and 3,209,971 shares of AMAG common stock. An […]
SYDNEY & AUCKLAND, New Zealand–(BUSINESS WIRE)–Living Cell Technologies Limited (LCT) today announced results from a Phase I/IIa clinical study of NTCELL®, an experimental regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease. The study, conducted in four patients in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well […]